CFDE Data Portal | Search R3HDM2P1

	Label	Description
	R3HDM2P1 associations Collection (Entity type)	Associations for R3HDM2P1_associations
	R3HDM2P1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	R3HDM2P1 Gene (Entity type)	ENSG00000248735 - R3H domain containing 2 pseudogene 1
	GSE176008 pyridoxine 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151083 enzalutamide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE164529 tamoxifen 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE164529 tamoxifen 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 10 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 pyridoxine 0 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS

R3HDM2P1 associations

Associations for R3HDM2P1_associations

R3HDM2P1 associations.tsv

A file from IDG as part of the Harmonizome project

R3HDM2P1

ENSG00000248735 - R3H domain containing 2 pseudogene 1

GSE176008 pyridoxine 4 v 3 human dn

A Gene Set from LINCS

GSE151083 enzalutamide 0 v 1 human up

A Gene Set from LINCS

GSE164529 tamoxifen 0 v 1 human dn

A Gene Set from LINCS

GSE195568 palbociclib 2 v 4 human dn

A Gene Set from LINCS

GSE164529 tamoxifen 0 v 2 human dn

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 10 v 8 human dn

A Gene Set from LINCS

GSE176008 pyridoxine 0 v 5 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.